You are here

Camurus

The biggest obesity deals of 2025 so far

Pharma Voice

Mon, 06/9/25 - 10:58 am

Carmot Therapeutics

United Laboratories International

Lilly inks deal worth up to $870M to develop long-acting GLP-1 obesity drugs

BioSpace

Wed, 06/4/25 - 09:39 am

FDA declines to approve Camurus' rare hormone disorder drug

Reuters

Tue, 10/22/24 - 11:24 am